Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Key Takeaways Eli Lilly reported a late-stage study of its oral weight-loss pill met primary and key secondary endpoints.The ...

Eli Lilly's experimental GLP-1 pill, orforglipron, demonstrated significant weight loss benefits in overweight adults with ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 ...

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

Eli Lilly has announced to go for global approval by the end of 2015 after completing the successful trials. The once-daily ...

Eli Lilly & Co’s experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, ...

Eli Lilly's experimental GLP-1 pill, orforglipron, showed promising results in a late-stage trial, aiding weight loss by 10.5 ...

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.